Haemophilia Drug Industry to Set Phenomenal Growth From 2024 to 2034 Shire , CSL, Grifols, Biogen, Octapharma, La Funcion mx - La Funcion mx

688520 Stock   37.21  0.79  2.08%   
About 61% of Sinocelltech's investor base is looking to short. The analysis of the overall investor sentiment regarding Sinocelltech Group suggests that many traders are alarmed. The current market sentiment, together with Sinocelltech's historical and current headlines, can help investors time the market. In addition, many technical investors use Sinocelltech Group stock news signals to limit their universe of possible portfolio assets.
  
Haemophilia Drug Industry to Set Phenomenal Growth From 2024 to 2034 Shire , CSL, Grifols, Biogen, Octapharma, La Funcion mx La Funcion mx

Read at news.google.com
Google News at Macroaxis
  

Sinocelltech Fundamental Analysis

We analyze Sinocelltech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinocelltech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinocelltech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Sinocelltech is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Sinocelltech Group Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sinocelltech stock to make a market-neutral strategy. Peer analysis of Sinocelltech could also be used in its relative valuation, which is a method of valuing Sinocelltech by comparing valuation metrics with similar companies.

Peers

Sinocelltech Related Equities

601166Industrial Bank   0.77   
0%
98.0%
601939China Construction   0.47   
0%
60.0%
601988Bank of China   0.38   
0%
48.0%
601857PetroChina   0.36   
0%
46.0%
600036China Merchants   0.29   
0%
37.0%
600938CNOOC   0.04   
0%
4.0%
601288Agricultural Bank   0.20   
25.0%
0%
601318Ping An   0.21   
26.0%
0%
601398Industrial   0.31   
39.0%
0%
600941China Mobile   0.78   
100.0%
0%

Complementary Tools for Sinocelltech Stock analysis

When running Sinocelltech's price analysis, check to measure Sinocelltech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinocelltech is operating at the current time. Most of Sinocelltech's value examination focuses on studying past and present price action to predict the probability of Sinocelltech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinocelltech's price. Additionally, you may evaluate how the addition of Sinocelltech to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing